现任药学院一级教授，博士生导师。研究方向为新药研究与开发，主持承担了科技部国家科技重大专项1项，国家自然科学基金8项，吉林省重点研发项目1项。在国内外发表学术论文200多篇，其中在J Med Chem, Acta Pharm Sin B, Eur J Med Chem等SCI期刊上发表170多篇。授权发明专利17项，其中1项获得临床批件，进入临床试验。获得吉林省科学技术二等奖和三等奖各2项，获得吉林省有突出贡献中青年专业技术人才、吉林省拔尖创新人才（第一层次）、吉林省长白山学者特聘教授、吉林省高级专家、延边大学图们江学者等荣誉。已培养硕士研究生73人，博士研究生20人。第九届中国药学会药物化学专业委员会委员，中国药物化学杂志编委。
【学习经历】
1981.9-1985.7 延边医学院，药学专业，学士学位
1989.9-1991.7 北京医科大学，药物化学专业，硕士学位
2003.9-2006.2 韩国圆光大学，药物化学专业，博士学位
【科研项目】
1. 基于青蒿素骨架的TgCDPK1/TgDHFR双靶抑制剂的设计、合成及抗弓形虫活性研究，国家自然科学基金，2025-2028
2. 基于牛蒡子苷元骨架的抗弓形虫活性分子的设计、合成及活性研究，国家自然科学基金，2020-2023
3. 呋喃香豆素类抗高血压候选药物Q1810的临床前研究，吉林省科技厅重点研发项目，2020-2022
4. 三嗪酮衍生物的合成及抗癫痫作用研究, 国家自然科学基金课题, 2017-2020
5. 抗癫痫候选药物 W112的研究，国家科技重大专项，2012-2015
【论文】
1. Hao Deng, Qian Xu, Guo-Qing Chen, Xing Huang, Jin-Ying Liu, Ya-Lan Wang, Yin-Sheng Quan, Rui Yan,Zhe-Shan Quan, Qing-Kun Shen. Design and synthesis of azole derivatives of echinocystic acid as α-glucosidase inhibitors with hypoglycemic activity. Eur J Med Chem, 2025, 289,117437
2. Qian Xu, Hao Deng, Xing Huang, Guo-Qing Chen, Yin-Sheng Quan, Ya-Lan Wang, Jin-Ying Liu, Rui Yan,Wen-Zhe Nie, Qing-Kun Shen, Zhe-Shan Quan, Hong-Yan Guo. Design, synthesis, and in vitro and in vivo biological evaluation of dihydroartemisinin derivatives as potent anti-cancer agents with ferroptosis-inducing and apoptosis-activating properties. Eur J Med Chem, 2025, 281, 117018
3. Hao Deng, Qian Xu, Xiao-Ting Li, Xing Huang, Jin-Ying Liu, Rui Yan, Zhe-Shan Quan, Qing-Kun Shen,Hong-Yan Guo. Design, synthesis, and evaluation of antitumor activity in Pseudolaric acid B Azole derivatives: Novel and potent angiogenesis inhibitor via regulation of the PI3K/AKT and MAPK mediated HIF-1/VEGF signaling pathway. Eur J Med Chem, 2024, 278, 116813
4. Hong-Yan Guo, Xiaoting Li, Xiao-Tong Sang , Zhe-Shan Quan* , Qing-Kun Shen*. Design and synthesis of forsythin derivatives as anti-inflammatory agents for acute lung injury. Eur J Med Chem, 2024, 267, 116223.
5. Fan-Fan Shang，Qing Lu, Tailiang Lin, Miaoxia Pu; Ruoxuan Xiao; Wanmei Liu ; Deng Hao; Hongyan Guo ; Zhe-Shan Quan; Chunyong Ding, Qing-Kun Shen. Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 Against Non-Small Cell Lung Cancer. J Med Chem，2023，66(18): 12931-12949
6. Zheng Liu, Xing Huang, Hong-Yan Guo, Lu-Wen Zhang, Yin-Sheng Quan, Fen-er Chen, Qing-Kun Shen, Zhe-Shan Quan. Design, synthesis fusidic acid derivatives alleviate acute lung injury via inhibiting MAPK/ NF-κB/NLRP3 pathway. Eur J Med Chem, 2023, 259, 115697
7. Lei Pang, Jin Li, Zheng Liu, Yin-Sheng Quan, He Huan Sui, Yi Jia, Fener Chen, Jung Joon Lee, Peng Liu, Zhe-Shan Quan, Qing-Kun Shen, Hon.g-Yan Guo. vitro and in vivo biological evaluation of newly synthesized multi-target 20(R)-panaxadiol derivatives for treating Alzheimer’s disease. Eur J Med Chem, 2022, 244, 114825
8. Fan-Fan Shang a, Jing YingWang, Qian Xu, Hao Deng, Hong-Yan Guo, Xuejun Jin,Xiaoting Li, Qing-Kun Shen, Zhe-Shan Quan. Design, synthesis of novel celastrol derivatives and study on theirantitumor growth through HIF-1a pathway. Eur J Med Chem, 2021, 220, 113474.
9. Lei Pang, Chun-Yan Liu, Guo-Hua Gong, Zhe-Shan Quan. Synthesis, in vitro and in vivo biological evaluation of novel lappaconitine derivatives as potential anti- inflammatory agents. Acta Pharmaceutica Sinica B, 2020, 10(4), 628-645
